Many papers have reported on pregnancy and delivery after liver transplantation, but there have been no reports on pregnancy after ABO-incompatible liver transplantation. This paper reports the first successful pregnancy and delivery of a newborn after ABOincompatible liver transplantation for fulminant hepatic failure. The patient was a 39-year-old female. She had an ABO-incompatible liver transplantation, donated from her husband, due to subacute fulminant hepatitis of unknown etiology. She was taking tacrolimus, methylprednisolone, and mizoribine orally for the maintenance of immunosuppression at the time of discharge. She was discharged uneventfully on postoperative day 38 without any rejection episodes. At 1 year and 6 mo after transplantation, she indicated a wish to become pregnant. Therefore, treatment with mycophenolate mofetil was interrupted at that time. After two miscarriages, she finally became pregnant and delivered transvaginally 3 years after the transplantation. All of the pregnancies were conceived naturally. The newborn was female with a birth weight of 3146 g; the Apgar scores were 9 and 10. Delivery was performed smoothly, and the newborn exhibited no malformations. The mother and the newborn were 
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INTRODUCTION
Liver transplantation has been established as a medical treatment for end-stage liver disease patients. In Japan, living-donor liver transplantation, including ABO-incompatible liver transplantation, is the most available procedure due to a chronic lack of deceased donor livers. We established a protocol for ABO-incompatible liver transplantation that uses immunosuppressants (e.g., cyclosporin or tacrolimus), rituximab, steroids, mizoribine, and intraportal infusion therapy [1, 2] . Although there are extensive operative stresses involved and immunosuppressants are required, many papers have reported a successful pregnancy or delivery after liver transplantation [3, 4] . However, only two reports described pregnancy and delivery after ABO-incompatible kidney transplantation, and there have been no reports on pregnancy after ABO-incompatible liver transplantation [5, 6] . This paper reports the first successful pregnancy and delivery of a newborn after ABO-incompatible liver transplantation for fulminant hepatic failure.
CASE REPORT
A 39-year-old woman, gravida 1, para 1, received an ABO-incompatible liver transplantation, donated from her husband. The transplantation was due to subacute fulminant hepatitis that occurred two months after her first delivery; although the etiology was unknown, it was suspected to be drug-induced. She had no appreciable diseases, including hepatitis virus infections, or a past or family history of liver disease. She was allergic to crab butter but not any medicines. Her blood type was O, Rh(+), and her HLA-A, B, DR was A2/A11, B35/B55, DR9/DR12. The donor's blood type was A, Rh(+), and his HLA-A, B, DR was A2/A24, B46/B48, DR8/DR16. Her anti-A and anti-B antibodies before hepatitis were uncertain due to a plasma exchange (PE).
She gave birth to her first baby by vaginal delivery at the age of 39 years old in February 2012. After delivery, she suffered from refractory periodontitis; she took the antibiotic cephem (cefdinir) for 6 d starting in April 2012 because of the periodontitis. Subsequently, she exhibited general malaise, general itching sensations, and chills. A dermatologist prescribed levocetirizine and prednisolone unguent, but the symptoms persisted with no improvement. She also had a problem with a second premolar tooth because she had exodontia and took the antibiotic cephem (cefdinir) to prevent infection. However, after taking this antibiotic, she experienced the sudden onset of jaundice and severe hepatic dysfunction , and she developed hepatic encephalopathy two weeks later, when the first symptoms appeared. On the day hepatic encephalopathy appeared, she was transferred to our hospital. We performed PE five times and started continuous hemodiafiltration. The first PE was fresh frozen plasma of blood type O, and the others were blood type AB due to the possibility of ABO-incompatible liver transplantation. Although she was registered on the waiting list for deceased donor liver transplantation in Japan, the progression of liver dysfunction did not allow for much time to be spent waiting for a deceased liver donation [the model for end-stage liver disease (MELD) score increased from 28 to 36 in a week]. In addition, pancreatitis was suspected due to the PEs because of the elevation in serum amylase. An ABO-incompatible liver transplantation was performed 10 d after the first PE was performed; the liver was donated from her 33-year-old husband. Before transplantation, her anti-A antibodies were 64 × (IgM) and 128 × (IgG), and her anti-B antibodies were 32 × (IgM) and 64 × (IgG).
The donor's left liver lobe (graft weight; 452 g, graft weight/recipient body weight = 0.93) was transplanted, and a splenectomy was also performed along with the insertion of an intraportal infusion catheter and immunosuppression, according to our protocol [1] for ABO-incompatible liver transplantation. Rituximab was infused one time just after the liver transplantation. The operation time was 10 h and 18 min, and blood loss was 538 mL.
Her encephalopathy improved promptly after the transplantation. She was extubated on postoperative day (POD) 3 and discharged from the intensive care unit on POD 7. Tacrolimus, steroids, and mizoribine were given, and intraportal infusion therapy was performed to prevent rejection (Figure 1) . The jaundice and liver function gradually improved, and she was discharged from the hospital on POD 38 with no bacterial infections or rejection episodes (laboratory data at the time of discharge: AST/ALT = 18/16 IU/L, T-Bil 15 μmol/L, D/T = 0.11, PT-INR = 1.08).
When she was discharged, she was taking tacrolimus (1.4 mg/d), methylprednisolone (mPSL; 15 mg/d), and mizoribine (200 mg/d) orally for the maintenance of immunosuppression, and her anti-A and anti-B antibodies were not increased; anti-A antibodies: 32 × (IgM) and 256 × (IgG), anti-B antibodies: 32 × (IgM) and 64 × (IgG). Although she developed steroidal diabetes, it was well controlled with insulin (HbA1c was within the range of 5.2%-6.1% during pregnancy).
Her serum tacrolimus concentration was maintained between 3 ng/mL and 8 ng/mL as an outpatient. Her general condition improved gradually, and 1 year and 6 mo after transplantation, she expressed a desire to become pregnant. Thereafter, she conceived spontaneously but miscarried twice, 2 years and 2 years plus 6 mo after the transplantation. Three years after the transplantation, when she was 42 years old, she conceived spontaneously, and the perinatal clinical course was uneventful. At the 39 th week of pregnancy, a female baby weighing 3146 g was delivered vaginally with Apgar scores of 9 and 10 at 1 and 5 min, 
DISCUSSION
ABO-incompatible living-related liver transplantation is a procedure that is performed to resolve the lack of deceased donors. Due to the immunosuppression protocol for ABO-incompatibility comprising rituximab [1] , it has become a relatively straightforward procedure. Our protocol for ABO-incompatible liver transplantation has allowed patients to undergo transplantation with a prognosis similar to that of an ABO-compatible liver [7] . This procedure greatly increases the likelihood of a successful transplantation in acute liver dysfunction patients who could not find an ABO-compatible donor. Indeed, in this case, the only donor available within the limited time was ABO incompatible. In the past, the survival rate of ABO-incompatible liver transplantation was lower than that of ABO-compatible transplantation, but with improvements, there is currently no significant difference between ABO-compatible and ABO-incompatible transplantation in the Japanese registry [8] .
Many papers have reported obstetric complications during pregnancy after liver transplantation; liver dysfunction and preeclampsia are commonly reported according to systematic reviews [9, 10] . The rates of cesarean section and preterm delivery are also higher after liver transplantation than in the general population; accordingly, gestational age is shorter after liver transplantation than in the general population. Fortunately, the perinatal course in our patient was uneventful. In contrast to previous reports [9, 10] , the patient delivered an appropriate-for-date newborn at full term.
Immunosuppression is an important point in pregnancy. The interruption of mizoribine use prevented teratosis, and no liver dysfunction was observed. Because mycophenolate mofetil was used, the patient needed a six-month interval before the pregnancy because of its teratogenic effects.
In conclusion, we experienced and reported the first successful management of a case of pregnancy after ABO-incompatible liver transplantation for fulminant hepatic failure.
COMMENTS

Case characteristics
The patient was a 39-year-old female. She had an ABO-incompatible liver transplantation, donated from her husband, due to subacute fulminant hepatitis of unknown etiology.
Clinical diagnosis
She was found to have jaundice, and hepatic encephalopathy was observed.
Differential diagnosis
Her differential diagnosis included drug-induced liver failure and viral infection.
Laboratory diagnosis
The laboratory evaluation showed significant hyperbilirubinemia, increased aspartate transaminase/alanine aminotransferase, hepatic dysfunction, and decreased prothrombin time-international normalized ratio.
Imaging diagnosis
Abdominal ultrasound and computed tomography revealed the atrophic change of the liver but no evidence of biliary obstruction.
Pathological diagnosis
She was diagnosed with drug-induced fulminant hepatitis upon liver biopsy.
Treatment
The initial treatment consisted of medical management comprising plasma exchange and continuous hemodiafiltration, followed by liver transplantation.
